



Astraea Therapeutics

Contact:

Nurulain T. Zaveri, PhD

Location:

Mountain View CA

Email:

nurulain@astraeatherapeutics.com

Tel:

650-254-0786

Website:

<http://www.astraeatherapeutics.com>



Company Profile

Industry Sector: Pharmaceuticals

Company Overview: Founded in 2009, Astraea Therapeutics is a privately held preclinical biopharmaceutical company, with a development pipeline of advanced small-molecule drug candidates for the treatment of central nervous system disorders.

Astraea's particular focus is on development of medications for smoking cessation treatment, substance abuse (alcohol, cocaine) treatment, sickle cell pain, chronic pain and Parkinson's disease.

Astraea's technology is centered on two major pharmacological targets implicated in CNS diseases, for which Astraea has deep, long-standing expertise and mature development programs.

Astraea's core competencies in innovative drug discovery are complemented by a well-defined path for translational development, and a mission to develop medications for unmet medical needs in CNS diseases.

Target Market(s): Smoking cessation, cocaine craving and relapse, alcohol use disorders, chronic pain market.



Key Value Drivers

Technology*: Astraea has drug candidate development programs at two major CNS targets.

For the nicotinic functional antagonists being developed for smoking cessation, Astraea's patented compounds are the first and only known high-affinity and highly selective compounds at the alpha3beta4 nicotinic receptor subtype. This nicotinic subtype is implicated in human genetic studies to be directly linked to smoking behaviors, and alcohol and cocaine addiction. Astraea's compounds show significant and potent efficacy in animal models of nicotine addiction and drug withdrawal.

Competitive Advantage: Unlike both varenicline (Chantix®) and bupropion (Zyban®), which do not prevent relapse to nicotine seeking, Astraea's compounds show high efficacy in blocking nicotine cue- and stress-induced relapse to nicotine seeking, in addition to blocking nicotine intake without producing withdrawal symptoms. *This distinction from currently available smoking cessation drugs can help with long-term abstinence rates and cravings.*

Plan & Strategy: Astraea plans to complete the IND development by the second half of 2016 and plans to seek strategic partnerships for FIH studies and clinical trials.



Management

Leadership: Nurulain T. Zaveri, PhD, President and Chief Scientific Officer, has over 20 years of experience in small-molecule drug discovery and development of novel medications for oncology and CNS therapeutics.

Astraea's scientific staff has a combined experience of 60 years in pharmaceutical drug discovery operations.

The Advisory team consists of experts in smoking cessation therapies, PK-ADME and toxicology development as well as an expert in CMC and Regulatory affairs. An expert patent and legal team support Astraea's patent portfolio and partnering activities.



Product Pipeline

DEVELOPMENT PIPELINE						
Target / Therapeutic Indication	Discovery	In Vivo Proof of Efficacy	Lead Optimization	Drug Candidate Selection	Preclinical Developmt	IND/ Phase I
Nicotinic Receptor Functional Antagonists for <i>Smoking Cessation</i>	[Progress bar spanning all stages]					
NOP/ μ Bifunctional Agonists <i>Non-addicting analgesics for Sickle Cell Pain</i>	[Progress bar spanning all stages]					
Nociceptin Receptor Agonists (<i>Cocaine addiction, Relapse</i>)	[Progress bar spanning all stages]					
Nociceptin Receptor Agonists (<i>Alcohol Addiction, Relapse</i>)	[Progress bar spanning all stages]					
NOP Partial Agonists for <i>Parkinsons Disease and Dyskinesia</i>	[Progress bar spanning all stages]					
Nicotinic Receptor Functional Antagonists for <i>Cocaine Addiction</i>	[Progress bar spanning all stages]					